The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 43 | Integrating immunotherapy in surgical oncology: insights on GI cancers and peritoneal malignancies
Pompiliu Piso, MD, Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany, discusses the importance of incorporating immunotherapy into surgical oncology practices. During an engaging session at the ESSO 2024 congress, he highlighted the promising activity of immunotherapeutic agents in gastrointestinal (GI) cancers, which could potentially reduce tumor masses and allow for subsequent surgical interventions. Additionally, he addressed the ongoing debate regarding the role of systemic chemotherapy in treating peritoneal surface malignancies, particularly concerning its timing relative to surgery. The discussions underscored the need for further studies, particularly the results from ongoing trials in the Netherlands, before establishing definitive recommendations.
This interview took place at the ESSO 2024 Congress in Antwerp, Belgium. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
